scispace - formally typeset
C

Christina C.N. Wu

Researcher at University of California, San Diego

Publications -  53
Citations -  1749

Christina C.N. Wu is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Chronic lymphocytic leukemia & Cytotoxic T cell. The author has an hindex of 19, co-authored 46 publications receiving 1621 citations. Previous affiliations of Christina C.N. Wu include University of California & Shenzhen University.

Papers
More filters
Journal ArticleDOI

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

TL;DR: Evidence is presented showing that a ligand of Toll-like receptor 7 (TLR7) can induce anti-HCV immunity not only by IFN induction, but also through an IFN-independent mechanism.
PatentDOI

Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas

TL;DR: In this article, the role of proteins involved in the Wnt/frizzled signaling pathway in proliferative disorders was investigated, which involves the roles of these proteins in proliferation disorders.
Journal ArticleDOI

Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.

TL;DR: CSCs express a type I receptor tyrosine kinase-like orphan receptor (ROR1), which is expressed during embryogenesis and by many different cancers, but not normal postpartum tissues, making ROR1 a potential target for the therapy of patients with ovarian cancer.
Journal ArticleDOI

Synthesis and Immunological Characterization of Toll-Like Receptor 7 Agonistic Conjugates

TL;DR: Data show that the immunostimulatory activity of a TLR7 ligand can be amplified and focused by conjugation, thus broadening the potential therapeutic application of these agents.
Journal ArticleDOI

Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand.

TL;DR: A versatile TLR7 agonist bearing a free aldehyde that could be coupled to many different auxiliary chemical entities through a linker molecule with a hydrazine or amino group without any loss of activity is synthesized, indicating the potential usefulness of the conjugate as a localized and targeted immunotherapeutic agent.